United States · FDA National Drug Code directory

Carbidopa and Levodopa

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
60219-2034_b5ad7e75-c6cd-4b2d-a3bf-e2e860d5b9c1
Product NDC
60219-2034
Form
TABLET, EXTENDED RELEASE
Composition / generic term
CARBIDOPA and LEVODOPA
Labeler
Amneal Pharmaceuticals NY LLC
Marketing category
ANDA
Marketing start / end (source format)
20221221
Source listing expiry
20271231

Source-listed ingredients

  • CARBIDOPA HYDRATE — 50 mg/1
  • LEVODOPA — 200 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (60219-2034-1) · 60219-2034-1
  • 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (60219-2034-3) · 60219-2034-3
  • 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (60219-2034-5) · 60219-2034-5

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →